GB736354A - Process for the production of preparation suitable as a blood plasma substitute - Google Patents
Process for the production of preparation suitable as a blood plasma substituteInfo
- Publication number
- GB736354A GB736354A GB1636/53A GB163653A GB736354A GB 736354 A GB736354 A GB 736354A GB 1636/53 A GB1636/53 A GB 1636/53A GB 163653 A GB163653 A GB 163653A GB 736354 A GB736354 A GB 736354A
- Authority
- GB
- United Kingdom
- Prior art keywords
- gelatine
- formaldehyde
- degradation
- treated
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003058 plasma substitute Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 8
- 239000001828 Gelatine Substances 0.000 abstract 7
- 229920000159 gelatin Polymers 0.000 abstract 7
- 235000019322 gelatine Nutrition 0.000 abstract 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 6
- 230000015556 catabolic process Effects 0.000 abstract 5
- 238000006731 degradation reaction Methods 0.000 abstract 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 4
- 239000011780 sodium chloride Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000007857 degradation product Substances 0.000 abstract 3
- 108010019160 Pancreatin Proteins 0.000 abstract 2
- 239000003610 charcoal Substances 0.000 abstract 2
- 229940055695 pancreatin Drugs 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 2
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 2
- ZTMADXFOCUXMJE-UHFFFAOYSA-N 2-methylbenzene-1,3-diol Chemical compound CC1=C(O)C=CC=C1O ZTMADXFOCUXMJE-UHFFFAOYSA-N 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- ASHGTJPOSUFTGB-UHFFFAOYSA-N methyl resorcinol Natural products COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 abstract 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001553 phloroglucinol Drugs 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A blood plasma substitute is produced by subjecting gelatine treated with formaldehyde to a partial degradation by means of protein splitting agents until the solubility of the gelatine is restored while maintaining the average molecular weight of the degradation product at a value of at least 20,000. The gelatine may be degraded by means of the fermentation agents of Specification 700,876, [Group IV (b)], or by acid or alkali treatment, degradation may take place concurrently with, or subsequently to, the hardening with formaldehyde. The treatment with formaldehyde may be carried out in the presence of a polyvalent phenol such as resorcinol, phloroglucinol or methyl resorcinol. The degradation product may be fractionated by precipitation by solvents such as acetone which are miscible with water. Physiological salts such as sodium chloride may be added. In examples, gelatine is treated with formaldehyde and hydrochloric acid, caustic soda or sodium carbonate or pancreatin and after degradation it is fractionated by means of acetone and optionally filtered through charcoal, sodium chloride is then added and the whole sterilized.ALSO:A blood plasma substitute is produced by subjecting gelatine treated with formaldehyde to a partial degradation by means of protein splitting agents until the solubility of the gelatine is restored while maintaining the average molecular weight of the degradation product at a value of at least 20,000 (see Group V). Physiological salts such as sodium chloride may be added. In examples, gelatine is treated with formaldehyde and hydrochloric acid, caustic soda or sodium carbonate or pancreatin and after degradation it is fractionated by means of acetone and optionally filtered through charcoal, sodium chloride is then added and the whole sterilized.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE736354X | 1952-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB736354A true GB736354A (en) | 1955-09-07 |
Family
ID=6642305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1636/53A Expired GB736354A (en) | 1952-01-28 | 1953-01-20 | Process for the production of preparation suitable as a blood plasma substitute |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB736354A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1118792B (en) * | 1958-01-22 | 1961-12-07 | Hoechst Ag | Process for the production of blood plasma substitutes from collagen breakdown products |
| US4064118A (en) | 1975-10-22 | 1977-12-20 | Hematech Inc. | Blood substitute based on hemoglobin |
-
1953
- 1953-01-20 GB GB1636/53A patent/GB736354A/en not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1118792B (en) * | 1958-01-22 | 1961-12-07 | Hoechst Ag | Process for the production of blood plasma substitutes from collagen breakdown products |
| US4064118A (en) | 1975-10-22 | 1977-12-20 | Hematech Inc. | Blood substitute based on hemoglobin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3396081A (en) | Hyaluronic acid preparation and method of producing same | |
| DK168297B1 (en) | Process for producing low molecular weight heparin from normal heparin | |
| CA1131408A (en) | Process for preparing soluble collagen fibres | |
| US3862003A (en) | Method of separating and recovering mucopolysaccharides from connective tissues of animals | |
| US3329572A (en) | Process for treating animal tissues and product | |
| HU190687B (en) | Process for preparing new antithrombotic of polysaccharide base further pharmaceutical compositions containing such substance as active material | |
| US2162863A (en) | Stable products shortening the bleeding period | |
| JPH05508184A (en) | Heparin derivatives and their production methods | |
| US10487135B2 (en) | Method for preparing low endotoxin collagen | |
| CN108977488B (en) | Elastin for intensive skin repair and preparation method thereof | |
| GB736354A (en) | Process for the production of preparation suitable as a blood plasma substitute | |
| GB769287A (en) | Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof | |
| GB1274940A (en) | Isolation of proteins | |
| US3936351A (en) | Method for preparing glucoronyl-glucosamino-glycan sulphates exhibiting antilipasaemic activity | |
| US2867567A (en) | Process of preparing anti-haemophilic globulin | |
| Polatnick et al. | Comparison of collagen preparations from beef cornea and sclera | |
| WO2023082523A1 (en) | Method for improving extraction rate of chondroitin sulfate prepared from tilapia skull | |
| CN104188902A (en) | Process for producing high-stability dalteparin sodium injection | |
| PT92163A (en) | METHOD FOR PREPARING A LIOFILIZED MDM COMPOSITION | |
| US6165490A (en) | Biological material, method of preparing such materials, uses thereof and products made therefrom | |
| RU2304441C1 (en) | Method for obtaining sulfated glycosaminoglycans out of biological tissues | |
| RU2748071C1 (en) | Method for obtaining individual fractions of matrix hyaluronate of various molecular weights of high fractional and chemical purity in a single technological cycle | |
| PL445948A1 (en) | Method of obtaining lyophilized collagen and glycosaminoglycans obtained from fish skin | |
| GB436576A (en) | Improved manufacture of gelatine for photographic purposes | |
| KR20220147996A (en) | Method for the preparation of high-purity heparin sodium |